Navigation Links
Details of HER-2/neu Class I Antigen Licensed by TapImmune published in Journal of Immunology: Antigen is a naturally processed epitope for breast cancer vaccines.
Date:1/22/2013

SEATTLE, Jan. 22, 2013 /PRNewswire/ -- TapImmune Inc. (OTCBB: TPIV) is pleased to announce the January publication of a paper titled "Enzymatic Discovery of a HER-2/neu Epitope That Generates Cross-Reactive T-cells", authored by Henle et al, J.Immunol. (2013), 190, 479-488.  This work, performed in the laboratory of Dr Keith Knutson at Mayo Clinic, describes the discovery of a novel HER-2/neu Class I epitope (p373-382) TapImmune has licensed from Mayo Clinic for the development of breast cancer vaccines.  The significance of this work is that this newly discovered antigen is a naturally occurring antigen processed by the proteasome and elicits peptide-specific T-cell responses.  This results in stronger binding to HLA-A2 and more efficient killing of HER-2/neu positive breast cancer cells by activated T-cells compared to the Class I epitope, p369-377 (E75) which was not naturally processed by the proteasome.

"These results provide an explanation of the molecular immunology behind our approach to HER-2/neu immunotherapy," said Mark Reddish Vice President of TapImmune Inc.  "These data describe how the HER-2/neu protein is processed by the proteasome to then be presented for immune recognition and killing.  By revealing the true identity of the immunodominant epitope responsible for class I mediated killing of HER-2/neu positive tumors, it is now possible to generate a true second generation vaccine that incorporates the correct target as it naturally appears on human tumors.  For nearly 20 years the immunology of this key protein has been clouded by contradictory observations, and these data finally provide an understanding of the 'natural target' displayed on human tumors. We expect to combine this immunodominant peptide with our broadly reactive helper peptides that are currently being tested in a phase I trial, to create a tru
'/>"/>

SOURCE TapImmune Inc.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. New Report Details NCPA Efforts to Drive Greater Medication Adherence
2. ADVENTRX Announces Details Of The Phase 3 Study Of ANX-188
3. CoLucid Pharmaceuticals Details Phase 3 Development Strategy for Lasmiditan to Address Major Unmet Needs in Acute Migraine Therapy
4. Young Innovations, Inc. Provides 2nd Quarter Conference Call Details
5. CryoLife Announces Release Date and Teleconference Call Details for 2012 Second Quarter Financial Results
6. Physician Details Problems with Medicare Approval Process for Power Wheelchairs
7. New Study Details Foreign Efforts To Lure Biopharmaceutical Companies
8. Robbins Arroyo LLP Announces the Filing of a Securities Fraud Class Action Lawsuit Against Hemispherx Biopharma, Inc.
9. MAQUET Cardiovascular Announces U.S. Food and Drug Administration Panel Votes To Reclassify Intra-Aortic Balloon Pumps To A Class II Designation In Certain Indications
10. Barrack, Rodos & Bacine Files Class Action Lawsuit Against St. Jude Medical, Inc.
11. Thomson Reuters Empowers Drug Development and Clinical Professionals to Develop Better, Faster Clinical Trials with Best-in-Class Intelligence Solution
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2013)... 16, 2013  PTC Therapeutics, Inc., today announced that ... with the U.S. Securities and Exchange Commission ("SEC") relating ... stock. The number of shares to be offered and ... determined. (Logo:  http://photos.prnewswire.com/prnh/20010919/PTCLOGO ) ... joint book-running managers for the offering. Cowen and Company ...
(Date:5/16/2013)... -- Alere Inc. (NYSE: ALR ), a global leader ... home through the merger of rapid diagnostics and health management, ... its Series B Convertible Perpetual Preferred Stock (NYSE: ALR.PR.B).  The ... record of Series B stock at the close of business ... the amount of all dividends accrued from April 1, 2013 ...
(Date:5/16/2013)... 2013  ULURU Inc. (OTCQB: ULUR) today announced its financial ... provided a review of its operating activities. Based ... previously communicated outlook for 2013: , Launching Altrazeal ® ... of distribution partners to cover all major markets excluding ... to be marketed in approximately 50 markets by the ...
Breaking Medicine Technology:PTC Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering 2ULURU Inc. Reports First Quarter 2013 Financial Results 2ULURU Inc. Reports First Quarter 2013 Financial Results 3ULURU Inc. Reports First Quarter 2013 Financial Results 4ULURU Inc. Reports First Quarter 2013 Financial Results 5
... Technologies, a global leader in scientific asset management, biomaterial ... in the AMDeC Vendor Partnership Program. This program provides ... products and services crucial to medical research and will ... BioStorage Technologies. AMDeC is a consortium ...
... 17, 2011 Ingenious Med, the leading platform for ... is now available on the App Store for iPhone, ... as part of the company,s presence at the Hospital ... enables Ingenious Med,s 9,000 users to access the charge ...
Cached Medicine Technology:BioStorage Technologies Partners with AMDeC, LLC to Provide Tissue Storage and Cold Chain Logistics Services to Academic Medical Research Institutions 2BioStorage Technologies Partners with AMDeC, LLC to Provide Tissue Storage and Cold Chain Logistics Services to Academic Medical Research Institutions 3HIMSS11: Ingenious Med Launches Billing and Data Capture App for iPhone, iPod touch and iPad 2
(Date:5/18/2013)... Utah (PRWEB) May 18, 2013 ... on insurance agents’ role in Marketplaces . ... to traditional employer sponsored health benefits, is the ... and health reimbursement arrangements . , ... Health and Human Services (HHS) recently released a ...
(Date:5/18/2013)... May 18, 2013 The Communities of ... special places we call home. These are the townships, villages ... are the locations where the people are friendly and neighbors ... viewers off the highways and shares the best in both ... nations with an American sports and film celebrity. It airs ...
(Date:5/18/2013)... “World Healthcare IT Market: Trends & Forecast (2010 – ... and opportunities in North America, Europe, Asia, & Rest ... 89 market data tables , 20 ... , http://www.marketsandmarkets.com/Market-Reports/healthcare-information-technology-market-136.html , Early buyers will ... IT market is expected to grow from $99.6 billion ...
(Date:5/18/2013)... FL (PRWEB) May 18, 2013 TheBeautyPlace.com ... Nioxin. Pattern hair loss is not a result of ... According to Men’s Fitness Magazine, 70% of men suffer ... Professional Strength is renowned for hair transplant surgery, ... fights male pattern baldness known as Bosley Professional Strength. ...
(Date:5/18/2013)... New York, New York (PRWEB) May 18, 2013 ... continue to mount in courts throughout the country, Bernstein ... that metal-on-metal hip replacement patients often suffer tissue damage ... During the study, which according to Science Daily will ... 69 metal-on-metal hip replacement recipients underwent MRI screens of ...
Breaking Medicine News(10 mins):Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 2Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 3Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 4Health News:Communities of Distinction TV Presents "A Place to Call Home" Segment 2Health News:Healthcare IT Market to reach US$ 162.2 Billion by 2015 at a CAGR of 10.2% - New Report by MarketandMarkets 2Health News:Healthcare IT Market to reach US$ 162.2 Billion by 2015 at a CAGR of 10.2% - New Report by MarketandMarkets 3Health News:TheBeautyPlace.com Features the Two New Best-Selling Hairloss Products: Bosley Professional Strength and Nioxin Systems 2Health News:TheBeautyPlace.com Features the Two New Best-Selling Hairloss Products: Bosley Professional Strength and Nioxin Systems 3Health News:Metal-on-Metal Hip Implants: Bernstein Liebhard LLP Comments on New Study Finding that Tissue Damage Precedes Pain in Metal-on-Metal Hip Replacement Patients 2Health News:Metal-on-Metal Hip Implants: Bernstein Liebhard LLP Comments on New Study Finding that Tissue Damage Precedes Pain in Metal-on-Metal Hip Replacement Patients 3Health News:Metal-on-Metal Hip Implants: Bernstein Liebhard LLP Comments on New Study Finding that Tissue Damage Precedes Pain in Metal-on-Metal Hip Replacement Patients 4
... every patient in Sweden having percutaneous coronary intervention ... coronary artery disease- has found that PCI implantations ... associated with lower rates of relapse (restenosis), stent ... stents and bare-metal stents.(1) The findings, from ...
... diagnosed with diabetes and hypertension have time to try ... without medications, but not too much time. ... to a year were smalla two-day reduction in quality-adjusted ... researchers published online for the Journal of General ...
... (HealthDay News) -- Inflammatory bowel disease (IBD) is becoming more ... Researchers who analyzed data from all population-based studies about the ... new cases is increasing or stable in virtually every region ... had the highest number of cases, while Asia had a ...
... There,s new evidence that annual prostate cancer screening does not ... 50s and 60s and those with underlying health conditions, according ... in St. Louis. A longer follow-up of more than ... years of aggressive, annual screening for prostate cancer led to ...
... doesn,t affect the quantity (or value) of imaging services received ... study in the January issue of the Journal of ... 51 million Americans, or 16.7 percent of the population, were ... of insurance is associated with less preventive care, delays in ...
... By Alan Mozes HealthDay Reporter , FRIDAY, Jan. ... to different people -- for some, anxiety and paranoia can ... a unique brain scan study suggests two ingredients in pot ... who watched the effects of the two marijuana ingredients -- ...
Cached Medicine News:Health News:New 'real-world' reassuring data from the SCAAR registry 2Health News:New 'real-world' reassuring data from the SCAAR registry 3Health News:For those with diabetes, controlling blood pressure is crucial, but not urgent 2Health News:For those with diabetes, controlling blood pressure is crucial, but not urgent 3Health News:As Nations Develop, So May Bowel Disease 2Health News:Mass prostate cancer screening doesn't reduce deaths 2Health News:Mass prostate cancer screening doesn't reduce deaths 3Health News:Paranoid or Placid? Scans Show Pot's Effect on Brain 2Health News:Paranoid or Placid? Scans Show Pot's Effect on Brain 3
... temporary internal drainage from the ureteropelvic junction ... stricture. The segment with no sideports prevents ... preventing ingrowth of the ureteral wall to ... Intended for one-time use. CAUTION: Periodic evaluation ...
... for temporary internal drainage from the ureteropelvic ... a stricture. The segment with no sideports ... while preventing ingrowth of the ureteral wall ... packages. Intended for one-time use. CAUTION: Periodic ...
ACMI™ 4.8 Fr Closed Tip Ureteral Stents are easily inserted through the 5 Fr working port of an endoscope. Large internal lumens enhance urinary flow, promoting the kind of drainage you might o...
... Used for retrograde ... and subsequent ureteral stent ... has a radiopaque band ... to aid in fluoroscopic ...
Medicine Products: